Wannenmacher M, Herfarth C
Radiologische Universitätsklinik, Heidelberg.
Chirurg. 2000 Dec;71(12):1440-6. doi: 10.1007/s001040051242.
Optimized surgical management is the most important factor influencing prognosis of patients suffering for rectal carcinoma. Oncologically radical surgical procedures with the intent of histologically complete resection should be performed, including excision of the tumour in total with sufficient margins in the oral and aboral directions. Total excision of the mesorectal tissue, at least in low-lying rectal tumours, is strongly recommended. Several retro- and prospective studies show that the surgeon him- or herself, using these adequate techniques, is the most important, statistically significant independent prognostic factor in patients with rectal carcinoma. In addition, adjuvant radiochemotherapy, given before or after surgery, decreases the local failure rates of high-risk patients (UICC stages II and III). Such radiochemotherapy is, to the great variety of different local failure rates in different surgical departments mandatory as recommended by the consensus conference of the German Cancer Society in July 1999. New and improved radiation techniques (conformal radiotherapy, intraoperative radiotherapy) could significantly decrease therapy-related toxicity, and innovative schedules (continuous low-dose 5-FU) may show increased therapeutic benefit of adjuvant treatment. Combined radiochemotherapy prior to surgery seems to increase the rate of sphincter-preserving procedures in low-lying rectal cancer. Definitive results and a clear advantage of pre- over postoperative radiochemotherapy (currently being tested in a German multicenter study) are still pending.
优化手术管理是影响直肠癌患者预后的最重要因素。应进行旨在实现组织学完全切除的肿瘤根治性手术,包括完整切除肿瘤,并在肿瘤上下缘保留足够的切缘。强烈建议至少对低位直肠癌患者完全切除直肠系膜组织。多项回顾性和前瞻性研究表明,运用这些恰当技术的外科医生本身,是直肠癌患者最重要的、具有统计学意义的独立预后因素。此外,术前或术后给予的辅助放化疗可降低高危患者(国际抗癌联盟II期和III期)的局部复发率。正如德国癌症协会1999年7月共识会议所建议的,鉴于不同外科科室局部复发率差异很大,这种放化疗是必需的。新的和改进的放疗技术(适形放疗、术中放疗)可显著降低治疗相关毒性,创新方案(持续低剂量5-氟尿嘧啶)可能显示辅助治疗的疗效增加。术前联合放化疗似乎可提高低位直肠癌保肛手术的比例。术前与术后放化疗的确切结果及明显优势(目前正在德国一项多中心研究中进行测试)仍有待确定。